Efficacy of lenvatinib versus sorafenib in the primary treatment of advanced hepatocellular carcinoma: A meta‐analysis

Abstract Background and Aim Molecular‐targeted agents such as lenvatinib and sorafenib have been approved to treat hepatocellular carcinoma (HCC). However, the choice between these two agents in the primary treatment for advanced HCC is still under debate with conflicting results. We sought to evalu...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	Vikash Jaiswal, Maha Hameed, Sidra Naz, Poulami Roy, Novonil Deb, Janta Ukrani, Gautham Varun Krishna Mohan, Amira M Taha, Helen Huang, Vikash Kumar, Bhavyakumar Vachhani, Abdelrahman M Attia, Supti D Nath, Mostafa A Solimn, Dattatreya Mukherjee
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	Wiley 2023-12-01
Σειρά:	JGH Open
Θέματα:	hepatocellular carcinoma lenvatinib mortality sorafenib
Διαθέσιμο Online:	https://doi.org/10.1002/jgh3.12999
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!